Document Detail

Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
MedLine Citation:
PMID:  12750692     Owner:  NLM     Status:  MEDLINE    
Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.
C H Hui; K Y Goh; D White; S Branford; A Grigg; J F Seymour; Y L Kwan; S Walsh; R Hoyt; A Trickett; B Rudzki; D D F Ma; L B To; T P Hughes
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Leukemia     Volume:  17     ISSN:  0887-6924     ISO Abbreviation:  Leukemia     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-16     Completed Date:  2003-06-04     Revised Date:  2013-03-04    
Medline Journal Info:
Nlm Unique ID:  8704895     Medline TA:  Leukemia     Country:  England    
Other Details:
Languages:  eng     Pagination:  821-8     Citation Subset:  IM    
1Haematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, SA, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD34 / metabolism
Antineoplastic Agents / therapeutic use*
Blood Component Removal
Cohort Studies
Enzyme Inhibitors / therapeutic use
Granulocyte Colony-Stimulating Factor / therapeutic use*
Hematopoietic Stem Cell Mobilization*
Hematopoietic Stem Cells / physiology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  genetics
Middle Aged
Philadelphia Chromosome
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use*
Recombinant Proteins
Remission Induction
Reverse Transcriptase Polymerase Chain Reaction
Treatment Outcome
Reg. No./Substance:
0/Antigens, CD34; 0/Antineoplastic Agents; 0/Enzyme Inhibitors; 0/Piperazines; 0/Pyrimidines; 0/Recombinant Proteins; 121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor; BKJ8M8G5HI/imatinib; EC Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Facemask therapy with rigid anchorage in a patient with maxillary hypoplasia and severe oligodontia.
Next Document:  Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI57...